Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Nurix Therapeutics (NRIX) Stock Price & Analysis
352 Followers
NRIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $18.12
Previous Close$14.44
Volume1.49M
Average Volume (3M)990.46K
Market Cap
$856.54M
Enterprise Value$835.89M
Total Cash (Recent Filing)$49.81M
Total Debt (Recent Filing)$29.16M
Price to Earnings (P/E)-5.4
Beta1.26
Next Earnings
Jul 10, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding49,150,794
10 Day Avg. Volume1,775,023
30 Day Avg. Volume990,459
Standard Deviation0.24
R-Squared0.19
Alpha-0.00671
Financial Highlights & Ratios
Price to Book (P/B)4.27
Price to Sales (P/S)41.73
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.33
Enterprise Value/Gross Profit10.86
Enterprise Value/Ebitda-6.11
Forecast
1Y Price Target
$25.09Price Target Upside73.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Nurix Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressNurix Therapeutics, Inc. presents compelling clinical evidence suggesting that their drug NX-5948 has a unique ability to cross the blood-brain barrier, which could mark a significant advancement in treating CNS lymphomas and potentially other neuroinflammatory diseases.
Financial HealthWith a solid cash position and sustained revenue streams, Nurix Therapeutics, Inc. stands on a firm financial foundation, which supports the continued development and potential commercial success of its drug candidates.
Strategic CollaborationsNurix's extended collaborations with industry giants like Sanofi and Gilead not only validate the company's innovative research capabilities but also provide a strong vote of confidence in its therapeutic pipeline, potentially narrowing the valuation gap with competitors.
Bears Say
Drug EfficacyA patient with primary central nervous system lymphoma experienced disease progression with a new brain lesion after initial complete response to NX-5948.
Financial PerformanceNurix reported a net loss of $2.65 per share—narrower than the previously estimated net gain of $0.26 per share; the difference predominantly can be attributed to lower-than-anticipated collaboration revenue.
Regulatory ChallengesNX-2127 remains on partial clinical hold, indicating some regulatory challenges and uncertainties in the drug's development pipeline.
---
Ownership Overview
14.89% Insiders
19.75% Mutual Funds
25.70% Other Institutional Investors
39.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $4.22 and its highest was $18.12 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Currently, no data Available
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Jul 10, 2024 which is in 82 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Apr 10, 2024. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.776 by $0.016.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -$0.69.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 59,317,460 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.776. Following the earnings report the stock price went down -10.24%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Among the largest hedge funds holding Nurix Therapeutics’s share is Baker Bros Advisors LP. It holds Nurix Therapeutics’s shares valued at 40M.
---
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.09 (73.75% Upside)
$25.09 (73.75% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 617.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.02%
12-Months-Change
Fundamentals
Return on Equity
-65.37%
Trailing 12-Months
Asset Growth
-15.53%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
---
NRIX Stock 12 Months Forecast
Average Price Target
$25.09
▲(73.75% Upside)
Technical Analysis
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+23.26%
reiterated a buy rating 3 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +23.26% per trade.
---